CD13 is a therapeutic target in human liver cancer stem cells

TLDR

Cancer stem cells are dormant or slowly cycling tumor cells that can reconstitute tumors, are linked to chemo‑ and radiation resistance and relapse, yet their existence and identity in many cancers remain poorly defined. CD13 protects cells from ROS‑induced DNA damage after genotoxic chemo/radiation stress and prevents apoptosis. CD13 marks semiquiescent CSCs in liver cancer that survive therapy, localize to relapse sites, and combining a CD13 inhibitor with 5‑FU markedly reduces tumor volume by suppressing CSC self‑renewal and enhancing chemotherapeutic efficacy.

Abstract

Cancer stem cells (CSCs) are generally dormant or slowly cycling tumor cells that have the ability to reconstitute tumors. They are thought to be involved in tumor resistance to chemo/radiation therapy and tumor relapse and progression. However, neither their existence nor their identity within many cancers has been well defined. Here, we have demonstrated that CD13 is a marker for semiquiescent CSCs in human liver cancer cell lines and clinical samples and that targeting these cells might provide a way to treat this disease. CD13+ cells predominated in the G0 phase of the cell cycle and typically formed cellular clusters in cancer foci. Following treatment, these cells survived and were enriched along the fibrous capsule where liver cancers usually relapse. Mechanistically, CD13 reduced ROS-induced DNA damage after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse xenograft models, combination of a CD13 inhibitor and the genotoxic chemotherapeutic fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 5-FU inhibited CD90+ proliferating CSCs, some of which produce CD13+ semiquiescent CSCs, while CD13 inhibition suppressed the self-renewing and tumor-initiating ability of dormant CSCs. Therefore, combining a CD13 inhibitor with a ROS-inducing chemo/radiation therapy may improve the treatment of liver cancer.